Millie
your market intelligence analyst
Search Results
24 results
Your search is now limited to «Clinical Trials» expert search.
American Diabetes Journals 11/20/2019 15:00
OBJECTIVE. Using real-world data (RWD) from three U.S. claims data sets, we aim to predict the findings of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA) comparing linagliptin versus glimepiride in patients with type 2 diabetes (T2D) at increased cardiovascular risk by using a novel framework that requires passing prespecified validity checks before analyzing the primary outcome. RESEARCH DESIGN AND METHODS. Within Medicare and two commercial claims data sets (May 2011–September 2015), we identified a 1:1 propensity score–matched (PSM) cohort of T2D patients 40–85 years old at increased cardiovascular risk who initiated linagliptin or glimepiride by adapting eligibility criteria from CAROLINA.
PR Newswire 11/18/2019 07:30
GERMANTOWN, Md., Nov. 18, 2019 /PRNewswire/ -- Triple-Gene LLC, a clinical stage cardiovascular gene therapy company and majority owned subsidiary of Intrexon Corporation (NASDAQ: XON), yesterday presented preliminary data from the Phase I trial (clinical trial identifier: NCT03409627) of...
World Pharma News 11/17/2019 19:00
While there is strong evidence demonstrating the efficacy of PCSK9 inhibitors from various randomized clinical trial studies, there is less information on the effectiveness of these medicines on cardiovascular outcomes in real-world practice.
GlobeNewswire 11/17/2019 15:05
We are very pleased with the pooled analyses from the Phase 3 LDL-C lowering clinical development program showing bempedoic acid not only lowered LDL-C by 25% but also reduced HbA1c by 0.19% in 1,134 patients with diabetes,” said Tim Mayleben, president and chief executive officer of Esperion ...

Personal Care

Household Products

Business Issues

Trends

Companies - Public

Companies - Venture Funded

Information Technologies

Regions

Job Titles